What is the curative effect of the approved indication of I drug Yingfeifan?
The approved indication of class I drug Infineon is to treat patients with unresectable stage III non-small cell lung cancer who have not progressed after receiving platinum-based chemotherapy and concurrent radiotherapy.
"I" drug is the only immunotherapy drug recommended by NCCN international guidelines for patients with stage III unresectable non-small cell lung cancer. The consolidation therapy of "I" drugs after concurrent chemoradiotherapy has improved the 3-year survival rate of patients to the highest level of 57%, which is a new breakthrough in stage III non-small cell lung cancer in recent years.
Usage and dosage of I medicine Yingfeifan
1. Original price and specifications of Yingfeifan: the price of Yingfeifan with 500mg specification is 18088 yuan/piece, while that of Yingfeifan with 120mg specification is 6066 yuan/piece.
The dosage is calculated by weight: 10 mg/kg.
Treatment cycle: once every two weeks.
How can lung cancer patients get Infineon's drug donation assistance?
In order to improve the accessibility and standardization of immunotherapy for lung cancer patients in China, reduce their economic burden and prolong their lives. On February 29th, 2020, the chinese primary health care Foundation officially launched the "Aiding Project for Patients with Lung Cancer Immunotherapy", and Duvacizumab injection was donated by AstraZeneca Investment (China) Co., Ltd. to the chinese primary health care Foundation for free.
It is reported that the introduction of the assistance plan will reduce the economic burden by hundreds of thousands of yuan a year and reduce the out-of-pocket expenses by more than 50%. Domestic patients with stage III lung cancer can enjoy exclusive good medicine at a lower price.
Aid scheme: buy 2 get 2 free, buy 4 get 4 free, buy 6 get 8 free.
1. assistance plan for low-income patients:
According to the doctor's advice, in the first round, patients used duvalizumab injection for 2 courses, and with the approval of the Foundation, they can use it for 2 courses.
According to the doctor's advice, the second round of patients used duvalizumab injection for 4 courses, and with the approval of the Foundation, it can be used as an assistant for 4 courses.
According to the doctor's advice, the third round patients used duvalizumab injection for 6 courses of treatment, and with the approval of the Foundation, they can use it for 8 courses. On the premise of no progress and continuous benefit, the project doctor confirms that patients can apply in cycles.
2. Assistance plan for low-income patients:
Follow the doctor's advice: with the approval of the foundation, assistance can be provided until the disease progresses.
It is worth noting that the following points are indicated in the drug donation plan:
① The aid object of this project is mainland patients with China people's ID card/military officer's card;
(2) The number of specific rescue projects shall be judged by the project doctor according to the patient's progress and clinical examination results;
③ Dosage of duvazumab injection should follow the instructions;
(4) The dosage of subsequent adjuvant drugs shall not exceed the dosage of drugs used in the early self-use stage.
Medical standards adopted by patients
① Infineon indications confirmed by pathology or cytology: stage ⅲ non-small cell lung cancer which has no disease progression and cannot be surgically removed after receiving platinum-containing chemotherapy and concurrent radiotherapy;
② Before the treatment of Duvalium injection, platinum-containing chemotherapy and concurrent radiotherapy were needed, and there was no disease progression;
③ Other PD- 1 or PD-L 1 inhibitors and chemotherapy drugs should not be given at the same time during the treatment with Duvalium injection;
④ The patient's physical condition can tolerate tumor immunotherapy;
⑤ There is sufficient clinical evidence to prove that patients can benefit from Infineon treatment without serious adverse reactions (benefit means that the tumor focus has no tumor progression according to RECIST 1. 1 standard; No serious adverse reaction means that there is no irreversible or intolerable damage caused by the treatment with Duvalium injection).
Economic standards for patients receiving donated drugs
1. Patients who have been diagnosed with non-small cell lung cancer and have been enjoying low security treatment during taking the medicine.
2. Patients receiving long-term treatment cannot afford the follow-up treatment expenses of Duvalium injection due to family economic reasons.
Time for accepting applications for drug donation
This project will be applied online, and the specific online time will be notified separately.